ESR1 and neoplasm: Investigations using additional scRNA‐seq datasets and dual immunohistochemistry (IHC) analysis on tumours from in vivo experiments with a CDK4/6 inhibitor supported our findings from ST analyses and characterised distinct roles and responses to oestrogen from proliferative cells in ER+ breast cancers.